Skip to Main Content

Paper Details

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia.
Blood Adv
7
2023
LBL, Nelarabine, T, T-ALL, T-cell acute lymphoblastic leukemia and lymphoma, T-cell acute lymphoblastic lymphoma/leukemia, anemia, children, cyclophosphamide, etoposide, nelarabine, neurotoxicity, patients, pediatric, stem cell, thrombocytopenia
Author NameAffiliation
Donna NeubergDana-Farber Cancer Institute
Richard M StoneDana-Farber Cancer Institute
Daniel J DeAngeloDana-Farber Cancer Institute
Marlise R LuskinDana-Farber Cancer Institute
  • 1 - 4

Datasets

Release 1.2